Member Info for Hazbeen

Beyond my pay grade

But great analysis JohnnyGee and thanks for sharing it

Disagree with that , jumping the gun a bit .

Capital market strategies include diversification, asset allocation, long-term investing, and short-term investing. These strategies help investors manage risk and maximize returns.

But a US listing , would push the share price a lot higher , as stocks are rated a lot higher

Sorry yes EPS IS LOWER THAN PREVIOUS quarter of previous year

Revenues and profits down accordingly

Do not get how a big drop can occur , must be weather related and seasonal

Anyway still avoiding these

Https://www.bseindia.com/xml-data/corpfiling/AttachLive/d59e33e3-a028-438d-bd11-0528b13f72fd.pdF

EPS is lower in comparison to Q3 2024 , not sure what debt is now

Nope

I reckon this will bought up after FDA approval at a nice premium to these levels

CEO adds again

Ondine Biomedical Inc. (AIM: OBI), a Canadian life sciences company pioneering light-activated antimicrobial treatments to treat and prevent multidrug-resistant infections, announces that The Pennycook Family Trust, controlled by Carolyn Cross, CEO, and Robert Cross, husband of Carolyn Cross, has purchased 200,775 shares ("Common Shares") in the Company at a price of 12 pence per Common Share on 30 January 2025.

Following this transaction, Carolyn Cross and Robert Cross, directly and indirectly, hold 156,064,804 Common Shares representing 35.3057% of the issued share capital of the Company.

Ndine Director increases stake in Company as Phase 3 clinical trial continues recruitment

Ondine Biomedical Inc. (AIM: OBI), a Canadian life sciences company pioneering light-activated antimicrobial treatments, announces that Margaret Shaw, Non-executive Director, has bought 30,000 shares ("Common Shares") in the Company at a price of 12 pence per Common Share on 29 January 2025.

Following this transaction, Margaret Shaw holds 243,853 Common Shares representing 0.0552% of the issued share capital of the Company.

Reserved

I have just read this funding takes runway to Q1 2027

Read one of previous RNS, it mentions it in there

Anyone have the research notes?

Singer Capital Markets has a target price of 65p for Ondine Biomedical Inc. (OBI). This is in relation to the company's Steriwave technology.

Explanation

Singer Capital Markets has a target price of 65p for OBI.

Research Tree also maintains a BUY rating and 65p price target for OBI.

Some investors are optimistic about OBI's prospects, citing the success seen in patients and the planned rapid recruitment of patients.

Reserved.

very good points

Nice to see this today

Hoping some good news will be out soon to explain this rise

Do you mind sharing how you have worked out those figures?

Hopefully not made from thin and there are some fundamentals behind them

Https://tinyurl.com/5xsb85cz

Do you find it odd, that cash is appeared on the balance sheet and debt is being paid down all after the investigations started

It all smells

Now funding has been sorted , US trials beginning on time

2025 will be a huge year for this company

Sell , years away to production

Explains M&G investment strategy and can see why they bought in here

Can Pension Funds Fuel The Growth Of UK Life Sciences?

hxxps://www.linkedin.com/pulse/can-pension-funds-fuel-growth-uk-life-sciences-matthew-neal-syade

Last week, ahead of the Mansion House speech, 5654 & Company hosted a networking breakfast with Citi Peel Hunt , LSEG (London Stock Exchange Group) and Covington & Burling LLP . The event brought together life sciences companies and investors for a keynote address, panel discussions, and a fireside chat on the potential impact of pension funds channelling their capital into growth opportunities, specifically to support the UK’s life sciences industry.

Investors such as Legal & General , Phoenix Group , Schroders Capital , M&G plc and Aviva Investors are well-positioned to lead this shift. He also discussed the untapped potential of the £400 billion in Local Government Pension Schemes (LGPS). The next day we heard the Chancellor’s intentions to consolidate LGPS into eight ‘MegaFunds’.

On the second panel, discussion centred around building critical mass in the UK life sciences market that will create competition and attract public market investors back to the sector. While Nasdaq dominates biotech listings, and will likely do so for some time, the UK’s strengths in medical devices, healthtech, tools, services and manufacturing should not be undersold and there is a route to the public markets for these. M&G's track record of success supporting the growth of UK life sciences companies through patient investment was also highlighted. This includes world leaders in their fields including Oxford Nanopore Technologies and Oxford Biomedica , and more recently it has invested into 4basebio and Ondine Biomedical Inc.

To attract investment, life sciences companies must present clear narratives and compelling equity stories. Transparent pension products focusing on tech and life sciences could shift investor perspectives from early-stage losses to long-term growth. By fostering collaboration between venture capital, pension funds, and institutions like the BBB, the UK can solidify its position as a global leader in life sciences innovation and compete effectively in the global market.

Leehc

What does the market price reaction tell you about today’s RNS .

Not all roses

So looks like MTL are gonna blow this cash everyone was hoping to get as dividends on acquisitions

The problem is these are not producing assets yet so will require more money , all comes with risks as CNR have already found out

Avoid MTL now , becoming not investable , and another lifestyle idea for the BoD